Date: 2011-10-17
Type of information: Fundraising
Company: Hookipa Biotech (Austria)
Investors:
Amount: €7 million
Funding type: series A financing round
Planned used: Hookipa Biotech has been founded in July 2011. The company has developed a proprietary technology platform, Vaxwave, dedicated to genetic vaccines for the prophylactic and therapeutic treatment of viral diseases. Vaxwave introduces a new approach to vaccination by providing long lasting and potent stimulation of both cellular and humoral immunity; the platform has been validated in different disease models. Hookipa Biotech will use the Series A funds to advance its lead product HB101 through pre-clinical development and a Phase I proof of concept study, and to further industrialize and validate the Vaxwave technology.
Others: Hookipa Biotech, a startup biotech company specialized in developing new generation vaccines, has raised €7 million Series A financing led by Sofinnova Partners. Forbion Capital Partners joined the syndicate as the co-investor.
Therapeutic area: Infectious diseases
